Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human varicella-zoster immune globulin
- Development stage
- Approved
- Lead developer
- Saol Therapeutics
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Human varicella-zoster immune globulin is a purified solution of human immunoglobulin G (IgG) containing high titers of antibodies against the varicella-zoster virus (VZV), the causative agent of chickenpox and shingles. It is used for post-exposure prophylaxis to prevent or reduce the severity of VZV infection in high-risk individuals, such as immunocompromised patients, pregnant women, premature infants, and newborns. The drug provides passive immunity by supplying anti-VZV antibodies that bind to viral proteins and neutralize the virus before it can cause severe disease. It does not treat established infections but is effective if administered within 4 days after exposure. Human varicella-zoster immune globulin is prepared from pooled plasma donated by healthy individuals with high levels of anti-VZV antibodies and undergoes processes such as solvent/detergent treatment, anion-exchange chromatography, pasteurization, and nanofiltration to ensure safety from viral transmission[1][4][5][6].
- Brand names
- VarizigZoster Immunoglobulin-VF
- Other names
- varicella zoster immune globulinVZIG
02
Targets
VZV gH/gL (Varicella-zoster virus glycoprotein H/glycoprotein L complex)gB (Human cytomegalovirus glycoprotein B)
Beyond the preview
Go deeper on human varicella-zoster immune globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human varicella-zoster immune globulin.